Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.37 |
| ▸ | SMYD2 | Q9NRG4 | 3/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | GLB1 | P16278 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL866009 | 1.00 | ALDH1A1 (0.42) | ALDH1A1CYP3A4SMYD2MAPK1HPGD | |
| SCHEMBL12803239 | 1.00 | ALDH1A1 (0.42) | ALDH1A1CYP3A4SMYD2MAPK1HPGD | |
| SCHEMBL12277057 | 1.00 | ALDH1A1 (0.42) | ALDH1A1CYP3A4SMYD2MAPK1HPGD | |
| SCHEMBL12936593 | 1.00 | ALDH1A1 (0.42) | ALDH1A1CYP3A4SMYD2MAPK1HPGD | |
| SCHEMBL16707269 | 1.00 | ALDH1A1 (0.42) | ALDH1A1CYP3A4SMYD2MAPK1HPGD | |
| SCHEMBL19464883 | 1.00 | ALDH1A1 (0.42) | ALDH1A1CYP3A4SMYD2MAPK1HPGD | |
| SCHEMBL17705851 | 0.89 | ALDH1A1 (0.35) | ALDH1A1CYP3A4SMYD2 | |
| SCHEMBL2587892 | 0.87 | SMYD2 (0.35) | ALDH1A1CYP3A4SMYD2HTTSMN1; SMN2 | |
| SCHEMBL31726850 | 0.86 | ALDH1A1 (0.39) | ALDH1A1CYP3A4SMYD2HPGD | |
| SCHEMBL8860952 | 0.85 | ALDH1A1 (0.40) | ALDH1A1CYP3A4SMYD2MAPK1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8022043-B2 | alpha -galactosylceramide; glycolipids; modulate NK T cells; autoimmune disease, cancer, type 1 diabetes | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 2011-09-20 | — | — | US | disclosed |
| US-8022043-B2 | alpha -galactosylceramide; glycolipids; modulate NK T cells; autoimmune disease, cancer, type 1 diabetes | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 2011-09-20 | — | — | US | disclosed |
| US-7772380-B2 | Ceramide derivatives as modulators of immunity and autoimmunity | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 2010-08-10 | — | — | US | disclosed |
| US-7772380-B2 | Ceramide derivatives as modulators of immunity and autoimmunity | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 2010-08-10 | — | — | US | disclosed |
| US-20090270431-A1 | Cyclopentenol Nucleoside Compounds Intermediates for their Synthesis and Methods of Treating Viral Infections | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION (US) | 2009-10-29 | — | — | US | disclosed |
| US-20070238673-A1 | Ceramide derivatives as modulators of immunity and autoimmunity | ALBERT EINSTEIN COLLEGE OF MEDICINE | 2007-10-11 | — | — | US | disclosed |
| US-20070238673-A1 | Ceramide derivatives as modulators of immunity and autoimmunity | ALBERT EINSTEIN COLLEGE OF MEDICINE | 2007-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270431-A1 | Cyclopentenol Nucleoside Compounds Intermediates for their Synthesis and Methods of Treating Viral Infections | REV1, NSUN2, ORC3 | ALDH1A1 1749/4885CYP3A4 291/4885SMYD2 3627/4885 |
| US-20070238673-A1 | Ceramide derivatives as modulators of immunity and autoimmunity | CERS2, UGCG, SGMS1 | ALDH1A1 4340/4885CYP3A4 4728/4885SMYD2 935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.